YKYohan Britto Kevorkian

Yohan Britto Kevorkian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yohan Britto Kevorkian has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Aline Campos De Azevedo Da Silva

    Serviço de Equivalência e Farmacocinética -SEFAR, Vice-Presidência de Produção e Inovação em Saúde-VPPIS, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

    1 shared publication
  • Amauri Alcindo Alfieri

    Laboratory of Animal Virology, Department of Preventive Veterinary Medicine, Universidade Estadual de Londrina, Londrina 86057-970, Paraná, Brazil

    1 shared publication
  • Ana Maria Coimbra Gaspar

    Laboratório de Desenvolvimento Tecnológico em Virologia, Oswaldo Cruz, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

    1 shared publication
  • Douglas Pereira Pinto

    Serviço de Equivalência e Farmacocinética -SEFAR, Vice-Presidência de Produção e Inovação em Saúde-VPPIS, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

    1 shared publication
  • Edilson Uiechi

    Libbs Indústria Farmacêutica, Embu, São Paulo, Brazil

    1 shared publication
  • Fernanda de Oliveira Bottino

    Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Expt Med & Hlth Lames, Rio De Janeiro, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy

    by Noemi Rovaris Gardinali, Juliana Rodrigues Guimarães, Juliana Gil Melgaço, Yohan Britto Kevorkian, Fernanda De Oliveira Bottino, Yasmine Rangel Vieira, Aline Campos De Azevedo Da Silva, Douglas Pereira Pinto, Laís Bastos Da Fonseca, Leandro Schiavo Vilhena, et al.

    Epidemiological studies found that hepatitis E virus genotype 3 (HEV-3) infection was associated with chronic hepatitis and cirrhosis in immunocompromised patients. Our study aimed to investigate the relationship between the host immunosuppressive status and the occurrence of HEV-related chronic hepatitis. Here we describe a successful experimental study, using cynomolgus monkeys previously treated with tacrolimus, a potent calcineurin inhibitor immunosuppressant, and infected with a Brazilian HEV-3 strain isolated from naturally infected pigs. HEV infected monkeys were followed up during 160 days post infection (dpi) by clinical signs; virological, biochemical and haematological parameters; and liver histopathology. The tacrolimus blood levels were monitored throughout the experiment. Immunosuppression was confirmed by clinical and laboratorial findings, such as: moderate weight loss, alopecia, and herpes virus opportunistic infection. In this study, chronic HEV infection was characterized by the mild increase of liver enzymes serum levels; persistent RNA viremia and viral faecal shedding; and liver histopathology. Three out of four immunosuppressed monkeys showed recurrent HEV RNA detection in liver samples, evident hepatocellular ballooning degeneration, mild to severe macro and microvesicular steatosis (zone 1), scattered hepatocellular apoptosis, and lobular focal inflammation. At 69 dpi, liver biopsies of all infected monkeys revealed evident ballooning degeneration (zone 3), discrete hepatocellular apoptosis, and at most mild portal and intra-acinar focal inflammation. At 160 dpi, the three chronically HEV infected monkeys showed microscopic features (piecemeal necrosis) corresponding to chronic hepatitis in absence of fibrosis and cirrhosis in liver parenchyma. Within 4-months follow up, the tacrolimus-immunosuppressed cynomolgus monkeys infected with a Brazilian swine HEV-3 strain exhibited more severe hepatic lesions progressing to chronic hepatitis without liver fibrosis, similarly as shown in tacrolimus-immunosuppressed solid organ transplant (SOT) recipients. The cause-effect relationship between HEV infection and tacrolimus treatment was confirmed in this experiment.